PLUS THERAPEUTICS, Inc.

PLUS THERAPEUTICS, Inc.

NNASDAQ:PSTV
1.60
USD
-0.18
(-10.11%)
-4.46EPS
31.94MMarket Cap

Total Valuation

USD

As of June 30, 2026, PLUS THERAPEUTICS, Inc. carries a market capitalization of 31.94M, placing it among publicly traded companies globally. Its enterprise value stands at 23.40M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap31.94M
Enterprise Value23.40M

Important Dates

PLUS THERAPEUTICS, Inc.'s next confirmed earnings release is scheduled for August 19, 2026.

Earnings Date8/19/2026

Share Statistics

As of June 30, 2026, PLUS THERAPEUTICS, Inc. has 7.31M shares outstanding.

Shares Outstanding7.31M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio5.85
P/TBV Ratio6.62
P/FCF Ratio-1.09
P/OCF Ratio-1.15

Financial Position

As of June 30, 2026, PLUS THERAPEUTICS, Inc. maintains a current ratio of 1.37, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.81, indicating moderate leverage, while an interest coverage ratio of -8.42 demonstrates limited ability to service its debt obligations.

Current Ratio1.37
Quick Ratio1.23
Debt / Equity0.81
Interest Coverage-8.42

Financial Efficiency

Over the twelve months ended June 30, 2026, PLUS THERAPEUTICS, Inc. posted a negative return on equity (ROE) of -614.05, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -214.01, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 26.25, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-614.05
Return on Assets (ROA)-214.01
Employee Count26.25

Stock Price Statistics

USD

As of the close on October 2, 2026, PLUS THERAPEUTICS, Inc.'s stock has declined approximately 90.62% over the past 52 weeks. The 50-day moving average sits at 2.89, while the 200-day moving average is 5.82.

52-Week Price Change-90.62%
50-Day Moving Average2.89
200-Day Moving Average5.82

Income Statement

USD

Over the twelve months ended June 30, 2026, PLUS THERAPEUTICS, Inc. generated - - in revenue and converted that into -26.09M in net income, yielding earnings per share of -4.46. EBITDA reached -25.94M, while operating income came in at -26.40M.

Operating Income-26.40M
Pretax Income-26.09M
Net Income-26.09M
EBITDA-25.94M
EBIT-26.40M
Earnings Per Share (EPS)-4.46

Balance Sheet

USD

As of June 30, 2026, PLUS THERAPEUTICS, Inc. holds 8.59M in cash and equivalents against 44,000.00 in total debt, resulting in a net debt position of -2.37M. Total book value stands at 5.46M, with working capital of 3.20M providing operational flexibility.

Cash & Cash Equivalents8.59M
Total Debt44,000.00
Net Debt-2.37M
Equity (Book Value)5.46M
Book Value Per Share0.75
Working Capital3.20M

Cash Flow

USD

PLUS THERAPEUTICS, Inc. produced -22.17M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.37M in capital expenditures, free cash flow totaled -23.55M - equivalent to -4.03 per share.

Operating Cash Flow-22.17M
Capital Expenditures-1.37M
Free Cash Flow-23.55M
FCF Per Share-4.03

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -92.16: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -79.06, meaning PLUS THERAPEUTICS, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-79.06
FCF Yield-92.16

Stock Splits

PLUS THERAPEUTICS, Inc.'s most recent stock split took place on April 2, 2026 with a 25:1 split ratio.

Last Split Date4/2/2026
Split Ratio25:1

Scores

As of June 30, 2026, PLUS THERAPEUTICS, Inc. has an Altman Z-Score of -59.57, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-59.57